Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., listed under the ticker LGST, is a clinical-stage biopharmaceutical company focused on T-cell immunotherapy, targeting infectious diseases and oncology indications. The company entered the public markets through a SPAC business combination in the healthcare and life sciences sector and filed an 8-K with the SEC on June 29, 2023, reflecting post-merger reporting activity. Operating in the cell therapy space, Tevogen Bio represents a newer class of biotech entrants that have used blank-check vehicles to access public capital markets. For complete filing histories, sponsor details, deal timelines, and SPAC analytics on Tevogen Bio Holdings and hundreds of other transactions, sign up for full data access at SpacDesk.